Patents by Inventor Christophe Queva

Christophe Queva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240173267
    Abstract: The present disclosure includes, among other things, lipids, compositions, and methods useful for delivering a polynucleotide or oligonucleotide, e.g., viral genome.
    Type: Application
    Filed: January 6, 2022
    Publication date: May 30, 2024
    Applicant: Oncorus, Inc.
    Inventors: Jessica Deterling, Sean Essex, Lorena Lerner, Qi-Ying Hu, Christophe Quéva
  • Publication number: 20240115636
    Abstract: The present disclosure relates to recombinant RNA molecules encoding an oncolytic virus genome. The present disclosure further relates to the encapsulation of the recombinant RNA molecules and the use of the recombinant RNA molecules and/or particles for the treatment and prevention of cancer.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 11, 2024
    Inventors: Lorena LERNER, Edward M. KENNEDY, Christophe QUÉVA, Jessica DETERLING, Jeffrey David BRYANT, Qi-Ying HU, Tooba A. CHEEMA, Sean ESSEX
  • Publication number: 20230241140
    Abstract: Oncolytic viral vectors that incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. Such viral vectors can be used for the treatment and prevention of cancer.
    Type: Application
    Filed: February 7, 2023
    Publication date: August 3, 2023
    Inventors: Mitchell H. FINER, Lorena LERNER, Christophe QUÉVA, Edward KENNEDY
  • Publication number: 20230235062
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Application
    Filed: November 1, 2022
    Publication date: July 27, 2023
    Inventors: CHRISTOPHE QUEVA, MICHELLE MORROW, SCOTT HAMMOND, MARAT ALIMZHANOV, JOHN BABCOOK, IAN FOLTZ, JASPAL SINGH KANG, LAURA SEKIROV, MELANIE BOYLE, MATTHIEU CHODORGE, ROSS A. STEWART, KATHLEEN ANN MULGREW
  • Publication number: 20230227577
    Abstract: The present disclosure provides anti-DLL3 binding constructs, such as anti-DLL3 single domain antibodies, as well as polynucleotide encoding the same. Further provided are multispecific binding constructs comprising the DLL3 binding domains described herein and polynucleotides encoding the same. Methods of production of the anti-DLL3 binding constructs and their use in the treatment of cancer are also provided herein.
    Type: Application
    Filed: May 5, 2021
    Publication date: July 20, 2023
    Inventors: Gholamreza HASSANZADEH GHASSABEH, Lorena LERNER, Sonia FEAU, Christophe QUÉVA
  • Publication number: 20230190931
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Application
    Filed: July 25, 2022
    Publication date: June 22, 2023
    Applicant: iTeos Belgium SA
    Inventors: Anthony COOPER, Christophe QUEVA, Sofie DENIES, Catherine HOOFD, Julia CUENDE, Gregory DRIESSENS, Florence LAMBOLEZ
  • Publication number: 20230181731
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Application
    Filed: September 16, 2022
    Publication date: June 15, 2023
    Applicant: iTeos Belgium SA
    Inventors: Anthony COOPER, Christophe QUEVA, Sofie DENIES, Catherine HOOFD, Julia CUENDE, Gregory DRIESSENS, Florence LAMBOLEZ
  • Patent number: 11612625
    Abstract: Oncolytic viral vectors that incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. Such viral vectors can be used for the treatment and prevention of cancer.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: March 28, 2023
    Assignee: Oncorus, Inc.
    Inventors: Mitchell H. Finer, Lorena Lerner, Christophe Quéva, Edward Kennedy
  • Patent number: 11518809
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: December 6, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcock, Ian Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew
  • Publication number: 20220380735
    Abstract: The present disclosure provides dual viruses capable of producing a primary virus and a secondary virus, and dual oncolytic viruses capable of producing a primary oncolytic virus and a secondary oncolytic virus.
    Type: Application
    Filed: October 9, 2020
    Publication date: December 1, 2022
    Inventors: Edward M. KENNEDY, Lorena LERNER, Christophe QUEVA, Craig A. STRATHDEE, Jennifer S. LEE
  • Patent number: 11439705
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: September 13, 2022
    Assignee: ITEOS BELGIUM SA
    Inventors: Anthony Cooper, Christophe Queva, Sofie Denies, Catherine Hoofd, Julia Cuende, Gregory Driessens, Florence Lambolez
  • Publication number: 20220117902
    Abstract: The present disclosure relates to recombinant RNA molecules encoding an oncolytic virus. The present disclosure further relates to the encapsulation of the recombinant RNA molecules and the use of the recombinant RNA molecules and/or particles for the treatment and prevention of cancer.
    Type: Application
    Filed: January 3, 2020
    Publication date: April 21, 2022
    Inventors: Lorena LERNER, Edward M. KENNEDY, Mitchell H. FINER, Christophe QUÉVA
  • Publication number: 20210017282
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Application
    Filed: July 23, 2019
    Publication date: January 21, 2021
    Inventors: CHRISTOPHE QUEVA, MICHELLE MORROW, SCOTT HAMMOND, MARAT ALIMZHANOV, JOHN BABCOCK, IAN FOLTZ, JASPAL SINGH KANG, LAURA SEKIROV, MELANIE BOYLE, MATTHIEU CHODORGE, ROSS A. STEWART, KATHLEEN ANN MULGREW
  • Publication number: 20200407445
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Application
    Filed: July 26, 2018
    Publication date: December 31, 2020
    Inventors: Anthony Cooper, Christophe Queva, Sofie Denies, Catherine Hoofd, Julia Cuende, Gregory Driessens, Florence Lambolez
  • Publication number: 20200206285
    Abstract: The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 2, 2020
    Inventors: Mitchell H. FINER, Lorena LERNER, Christophe QUÉVA, Edward KENNEDY
  • Publication number: 20190315867
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Application
    Filed: May 15, 2019
    Publication date: October 17, 2019
    Inventors: Anthony Cooper, Christophe Queva, Sofie Denies, Catherine Hoofd, Julia Cuende, Gregory Driessens, Florence Lambolez
  • Patent number: 10400039
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: September 3, 2019
    Assignee: MEDIMMUNE LIMITED
    Inventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcock, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew
  • Patent number: 10329349
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: June 25, 2019
    Assignee: iTeos Therapeutics SA
    Inventors: Anthony Cooper, Christophe Queva, Sofie Denies, Catherine Hoofd, Julia Cuende, Gregory Driessens, Florence Lambolez
  • Publication number: 20190100591
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 4, 2019
    Inventors: Anthony Cooper, Christophe Queva, Sofie Denies, Catherine Hoofd, Julie Cuende, Gregory Driessens, Florence Lambolez
  • Publication number: 20180353512
    Abstract: Provided herein are methods that relate to a therapeutic strategy for treatment of a B-cell malignancy. In particular, the methods include administration of a PI3K inhibitor and a BTK inhibitor.
    Type: Application
    Filed: June 22, 2016
    Publication date: December 13, 2018
    Inventors: Helen Collins, Julie Di Paolo, Kathy Keegan, Ryohei Kozaki, Sarah Meadows, Cara Nelson, Christophe Queva, Srinivasan Ramanathan, Stacey Tannheimer, Daniel Tumas, Tomoko Yasuhiro, Toshio Yoshizawa